UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2012


o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number 333-156942

Rx Technologies Corp.

(Exact name of registrant as specified in its charter)


Florida		26-3891952
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)


7076 Spyglass Avenue, Parkland, Florida		33076
(Address of principal executive offices)		(Zip Code)

(954) 599-3672

(Issuer’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	þ

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at ~~July~~October 2015, 2012
Common Stock, $0.001		94,441,850 shares

RX TECHNOLOGIES CORP.

TABLE OF CONTENTS

PAGE Part I Financial Information 3 Item 1. Financial Statements 3 Condensed Balance Sheets at ~~June~~September 30, 2012 (unaudited) and December 31, 2011 (audited) 3 Condensed Statements of Operations for the three and ~~six~~nine months ended ~~June~~September 30, 2012 and 2011 and the cumulative period from November 15, 2008 (inception) through ~~June~~September 30, 2012 4 Condensed Statements of Cash Flows at ~~June~~September 30, 2012 and 2011 and the cumulative period from November 15, 2008 (inception) through September 30, 2012 5 Notes to Condensed Financial Statements 6 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 1210 Item 3. Quantitative and Qualitative Disclosures About Market Risk. 1513 Item 4. Controls and Procedures. 1514 Part II Other Information 1614 Item 1. Legal Proceeding. 1614 Item 1A. Risk Factors. 1614 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 1614 Item 3. Defaults Upon Senior Securities. 1614 Item 4. Mine Safety Disclosures. 1615 Item 5. Other Information. 1615 Item 6. Exhibits. 1615 Signatures 1615

- 2 -

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEETS

ASSETS
	June 30, 2012			December 31, 2011
	(unaudited)			(audited)
CURRENT ASSETS:
Cash and equivalents	$	—		$	—
Inventory		—			—
Total Current Assets		—			—
OTHER ASSETS:
Intellectual Property:
Gift Card Digest Website, net		—			—
RxTC Solutions		10,000			10,000
Medipayments		10,000			10,000
Total Other Assets		20,000			20,000
Total Assets	$	20,000		$	20,000
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
CURRENT LIABILITIES:
Accounts Payable		—			—
Accrued Expenses		3,750			7,250
Advances from Related Parties		—			5,700
Total Current Liabilities		3,750			12,950
Long-term Liabilities
Total Long-term Liabilities		—			—
Total Liabilities		3,750			12,950
STOCKHOLDERS’ EQUITY/(DEFICIT):
Preferred Stock, par value $.001; 10,000,000 shares authorized;
0 issued and outstanding at June 30, 2012 and December 31, 2011		—			—
Common stock, par value $.001; 500,000,000 shares authorized;
94,441,850 shares issued and outstanding at June 30, 2012;
78,121,850 shares issued and outstanding at December 31, 2011		94,442			78,122
Additional paid in capital		144,680			132,600
Deficit accumulated during the development stage		(222,872	)		(203,672	)
Total Stockholders’ Equity		16,250			7,050
Total Liabilites and Stockholder’s Equity (Deficit)	$	20,000		$	20,000

(Unaudited)

The accompanying notes are an integral part of these statements.


ASSETS

	September 30, 2012			December 31, 2011
CURRENT ASSETS:
Cash and equivalents	$	—		$	—

Total Current Assets		—			—

OTHER ASSETS:
Intellectual Property:
Gift Card Digest Website, net		—			—
RxTC Solutions, net		2,500			10,000
Medipayments, net		2,500			10,000
Total Other Assets		5,000			20,000

Total Assets	$	5,000		$	20,000

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)

CURRENT LIABILITIES:
Accrued Expenses		3,500			7,250
Advances from Related Parties		9,000			5,700
Total Current Liabilities		12,500			12,950

Total Liabilities		12,500			12,950

STOCKHOLDERS’ EQUITY/(DEFICIT):
Preferred Stock, par value $.001; 10,000,000 shares authorized;
0 issued and outstanding at September 30, 2012 and December 31, 2011		—			—
Common stock, par value $.001; 500,000,000 shares authorized;
94,441,850 shares issued and outstanding at September 30, 2012;
78,121,850 shares issued and outstanding at December 31, 2011		94,442			78,122
Additional paid in capital		144,680			132,600
Deficit accumulated during the development stage		(246,622	)		(203,672	)
Total Stockholders’ Equity		(7,500	)		7,050

Total Liabilites and Stockholder’s Equity (Deficit)	$	5,000		$	20,000

The accompanying notes are an integral part of these unaudited financial statements.

- 3 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS

													Cumulative from
													November 15, 2008
	For the three			For the three			For the six			For the six			(Inception)
	months ended			months ended			months ended			months ended			through
	June 30, 2012			June 30, 2011			June 30, 2012			June 30, 2011			June 30, 2012
Net Sales	$	—		$	—		$	—		$	—		$	—
Cost of Sales		—			—			—			—			—
Gross Profit		—			—			—			—			—
Expenses:
General & Administrative		2,400			2,350			5,200			3,850			23,025
Legal and Accounting		2,500			4,250			4,000			5,250			39,625
Fees to Directors		—			—			—			—			25,000
Consulting, Marketing and Advertising		5,000			—			10,000			15,000			87,000
Amortization and Impairments		—			—			—			1,834			48,222
Total Expenses		9,900			6,600			19,200			25,934			222,872
Net (loss) before Income Taxes		(9,900	)		(6,600	)		(19,200	)		(25,934	)		(222,872	)
Provision for Income Taxes		—			—			—			—			—
Net (loss)	$	(9,900	)	$	(6,600	)	$	(19,200	)	$	(25,934	)	$	(222,872	)
Basic and diluted net loss per common share	$	(0.0001	)	$	(0.0001	)	$	(0.0002	)	$	(0.0004	)
Weighted average number of common shares outstanding		84,630,861			64,341,850			81,411,520			61,800,994

(Unaudited)

The accompanying notes are an integral part of these statements.


													Cumulative from
													November 15, 2008
	For the three			For the three			For the nine			For the nine			(Inception)
	months ended			months ended			months ended			months ended			through
	September 30, 2012			September 30, 2011			September 30, 2012			September 30, 2011			September 30, 2012

Net Sales	$	—		$	—		$	—		$	—		$	—

Cost of Sales		—			—			—			—			—

Gross Profit		—			—			—			—			—

Expenses:
General & Administrative		2,750			1,800			3,750			5,650			21,575
Legal and Accounting		3,500			2,000			7,500			7,250			43,125
Fees to Directors		—			—			—			—			25,000
Consulting, Marketing and Advertising		2,500			—			16,700			15,000			93,700
Amortization and Impairments		15,000			—			15,000			1,834			63,222

Total Expenses		23,750			3,800			42,950			29,734			246,622

Net (loss) before Income Taxes		(23,750	)		(3,800	)		(42,950	)		(29,734	)		(246,622	)

Provision for Income Taxes		—			—			—			—			—

Net (loss)	$	(23,750	)	$	(3,800	)	$	(42,950	)	$	(29,734	)	$	(246,622	)

Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding		94,441,850			66,121,850			85,754,964			63,262,359

The accompanying notes are an integral part of these unaudited financial statements.

- 4 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF CASH FLOWS

For the Period November 15, 2008 (inception) through ~~June~~September 30, 2012

							Cumulative from
							November 15, 2008
	For the six			For the six			(Inception)
	months ended			months ended			through
	June 30, 2012			June 30, 2011			June 30, 2012
OPERATING ACTIVITIES:
Net loss	$	(19,200	)	$	(25,934	)	$	(222,872	)
Adjustments to reconcile net loss to net cash used in operating activities:
Increase in amortization		—			1,834			6,000
Stock issued for services		10,000			10,000			105,000
Conversion of related shareholders advances		18,400			16,500			34,900
Impairment loss		—			—			42,222
Changes in operating assets and liabilities:
Acquisition of intellectual property		—			—			(6,000	)
Increase/(Decrease) in accounts payable and accrued expenses		(3,500	)		(2,400	)		3,750
Net cash (used in) provided by operating activities		5,700			—			(37,000	)
FINANCING ACTIVITIES:
Increase/(decrease) in due to related parties		(5,700	)		—			18,000
Increase in notes payable		—			—
Proceeds from issuance of common stock		—			—			19,000
Net cash provided by (used in) financing activities		(5,700	)		—			37,000
NET INCREASE (DECREASE) IN CASH		—			—			—
CASH BEGINNING BALANCE		—			—			—
CASH ENDING BALANCE		—			—			—
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Taxes paid	$	—		$	—		$	—
Interest paid	$	—		$	—		$	—
NON-CASH TRANSACTIONS AFFECTING OPERATING, INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock for acquisition of intellectual property	$	—		$	25,000		$	62,222
Repayment of related party loan with stock	$	18,400		$	—		$	36,400

(Unaudited)

The accompanying notes are an integral part of these statements.


							Cumulative from
							November 15, 2008
	For the nine			For the nine			(Inception)
	months ended			months ended			through
	September 30, 2012			September 30, 2011			September 30, 2012

OPERATING ACTIVITIES:
Net loss	$	(42,950	)	$	(29,734	)	$	(246,622	)
Adjustments to reconcile net loss to net cash used in operating activities:
Increase in amortization and impairment		15,000			1,834			63,222
Stock issued for services		16,700			26,500			128,200

Changes in operating assets and liabilities:
Acquisition of intellectual property		—			—			(6,000	)
Increase/(Decrease) in accounts payable and accrued expenses		2,250			(1,900	)		9,500

Net cash (used in) provided by operating activities		(9,000	)		(3,300	)		(51,700	)

FINANCING ACTIVITIES:
Increase (decrease) in due to related parties		9,000			3,300			32,700
Increase in notes payable		—			—			—
Proceeds from issuance of common stock		—			—			19,000

Net cash provided by (used in) financing activities		9,000			3,300			51,700

NET INCREASE (DECREASE) IN CASH		—			—			—

CASH BEGINNING BALANCE		—			—			—

CASH ENDING BALANCE		—			—			—

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Taxes paid	$	—		$	—		$	—
Interest paid	$	—		$	—		$	—

NON-CASH TRANSACTIONS AFFECTING OPERATING, INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock for related party advances	$	11,700		$	16,500		$	28,200
Issuance of common stock for acquisition of intellectual property	$	—		$	—		$	62,222
Issuance of notes payable for acquisition of intellectual property	$	—		$	—		$	18,000

The accompanying notes are an integral part of these unaudited financial statements.

- 5 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

~~JUNE~~SEPTEMBER 30, 2012

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for the presentation of interim financial information, but do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. The audited financial statements for the period November 15, 2008 (Inception) through December 31, 2011 and the year ended December 31, ~~2011~~2010 were filed on February 23, 2012 with the Securities and Exchange Commission and are hereby referenced. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the ~~six~~nine months ended ~~June~~September 30, 2012 and for the period November 15, 2008 (Inception) through ~~June~~September 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

NOTE 2 - DESCRIPTION OF BUSINESS AND DEVELOPMENT STAGE RISK

Description of Business

RX TECHNOLOGIES CORP. (“THE COMPANY”) is a development stage company, incorporated in the State of Florida on November 15, 2008. The company is focusing in the development of two (2) databases, at ~~June~~September 30, 2012 as follows:

RxTC Database The RxTC database is for prescription drug databases. The RxTC Solutions is a secure, easy-to-use and minimum cost service for confronting prescription drug abuse and diversion. The RxTC solution is a comprehensive secure validation, monitoring and reporting procedure integrated with a visual identification verification system. The process immediately prevents “doctor shopping,” individuals going to more than one physician at a time to obtain prescription drugs. By deploying the RxTC solution, patient’s identities can be verified and validated. Physicians and pharmacists will immediately have live, real-time data available for scrutiny and could receive important alerts and valid dispensing histories. Secondary verification at the point of dispensing could further eliminate the potential for fraud and other more serious crimes. Medipayment Database The Medipayment process includes a system whereby merchants that utilize the process have additional identifying features of the consumer to enhance correct identification on presentation and process of the facility. Additionally, Medipayments is developing vending dispensaries and tech messaging services in the related fields of technology.

The RxTC database is for prescription drug databases. The RxTC Solutions is a secure, easy-to-use and minimum cost service for confronting prescription drug abuse and diversion. The RxTC solution is a comprehensive secure validation, monitoring and reporting procedure integrated with a visual identification verification system. The process immediately prevents “doctor shopping,” individuals going to more than one physician at a time to obtain prescription drugs. By deploying the RxTC solution, patient’s identities can be verified and validated. Physicians and pharmacists will immediately have live, real-time data available for scrutiny and could receive important alerts and valid dispensing histories. Secondary verification at the point of dispensing could further eliminate the potential for fraud and other more serious crimes.

Medipayment Database

The Medipayment process includes a system whereby merchants that utilize the process have additional identifying features of the consumer to enhance correct identification on presentation and process of the facility. Additionally, Medipayments is developing vending dispensaries and tech messaging services in the related fields of technology.

We commenced our initial public offering on May 21, 2009, pursuant to that certain Registration Statement on Form S-1 (Commission File No. 333-156942), which was declared effective by the Securities and Exchange Commission on that date. We registered 3,000,000 shares of Common Stock for sale by the Company for an aggregate offering price of $30,000. We sold 1,000,000 shares of Common Stock in the offering. The offering provided proceeds to us in the amount of $10,000.

On April 28, 2010, we filed Amended and Restated Articles of Incorporation with the Secretary of State of Florida which:


·	changed the name of the corporation to Rx Technologies Corp.,

·	increased the number of authorized shares of common stock from 100,000,000 shares to 500,000,000 shares and fixed a par value of $0.001 per share,

·	authorized a class of 10,000,000 shares of blank check preferred stock, par value $0.001 per share, and

·	included indemnification provisions customary under Florida law, as well as election not to be governed by the provisions of the Florida Business Corporation Act governing affiliated transactions and an election to be governed by the provisions related to control share acquisitions.

- 6 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

~~JUNE~~SEPTEMBER 30, 2012

On April 30, 2010, we entered into an Intellectual Property Agreement with the developer and owner of the RxTC database processes for prescription drug databases. Pursuant to this agreement, the Company acquired solely the intellectual property and related rights. The total consideration for the intellectual property purchased was the issuance of 37,221,850 common shares of our company. The issued common shares were allocated, in part, to certain other associates involved with facilitating the development of the intellectual property as defined in the Intellectual Property Agreement.

On February 25, 2011, we entered into an Intellectual Property Agreement with Medipayments, Inc., the developer and owner of the Medipayment’s process for merchant services including trade secrets and intellectual property rights. The total consideration for the intellectual property purchased was the issuance of 5,000,000 common shares of our company. The Medipayment process includes a system whereby merchants that utilize the process have additional identifying features of the consumer to enhance correct identification on presentation and process of the facility. Additionally, Medipayments is developing vending dispensaries and tech messaging services in the related fields of technology.

As of ~~June~~September 30, 2012, we had an accumulated deficit of ($~~222~~246,~~872~~622). Our auditors have raised substantial doubt as to our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There can be no assurance that we will operate at a profit or such additional financing will be available, or if available, can be obtained on satisfactory terms.

Our principal executive office is located at 7076 Spyglass Avenue, Parkland, FL 33076. Our telephone number is (954) 599-3672. Our fiscal year ends on December 31.

Basis of Presentation

The accompanying condensed financial statements have been prepared by the Company. The Company’s financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

Going Concern

The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management’s Plan to Continue as a Going Concern

The Company has met its historical working capital requirements from the sale of its capital shares and loans from officers, directors, related parties and stockholders. In order to continue as a going concern, the Company will need, among other things, additional capital resources.

Management’s plans to obtain such resources for the Company include obtaining capital from the sale of shares of common stock of the Company and/or financing from independent third parties. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

Development Stage ~~Risk~~

Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. Our ability to execute our business plan will depend on our ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, we cannot give any assurance that we will generate substantial revenues or that our business operations will prove to be profitable.

- 7 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

~~JUNE~~SEPTEMBER 30, 2012

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~Cash and Cash Equivalents~~Reclassifications

~~The~~Certain ~~Company~~prior ~~considers~~year ~~all~~amounts ~~highly~~have ~~liquid~~been ~~debt~~reclassified ~~instruments with original maturities of three months or less~~ to beconform ~~cash~~with ~~equivalents.~~the ~~The~~current ~~Company~~year ~~has no cash equivalents~~presentation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Inventories

Inventories are valued at the lower of cost or market on a first-in, first-out (FIFO) basis, and include finished goods. Inventories consist of various gift cards having various denominations at cost.

Intellectual Properties

The ~~company~~Company accounts for its two (2) primary intellectual properties at lower cost to market value and amortize over the useful life of the asset. The company’s two (2) primary intellectual properties are under development and have not been placed in service at ~~June~~September 30, 2012.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. For the ~~twelve~~nine (129) months ended ~~December~~September 3130, ~~2011~~2012, management determined that there should be an impairment expense of ~~valuations~~$15,000 to ~~intellectual property. Therefore, for~~ the ~~year~~valuations ~~ending~~of ~~December~~intellectual ~~31, 2011, impairment expense was $42,222~~property.

~~Revenue~~Impairment ~~Recognition~~of Long-Lived Assets

In accordance with ASC 360-10-05-4 “Property, Plant, and Equipment-Impairment or Disposal of Long-Lived Assets”, which was previously Financial Accounting SFAS No.144, “Accounting for the Impairment or Disposal of Long-lived Assets”, the Company assesses long-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. Recoverability of asset groups to be held and used in measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of an asset group exceeds the fair value of the asset group. The Company ~~recognizes~~evaluates ~~revenue~~its ~~when:~~long-lived assets from time to time and impairment charges of $15,000 were recorded for the three (3) month period ended September 30, 2012.

· Persuasive evidence of an arrangement exists; · Shipment has occurred; · Price is fixed or determinable; and · Collectability is reasonably assured.

The Company closely follows the provisions of Accounting Standards Codification (“ASC”) 605, Revenue Recognition, which includes the guidelines of Staff Accounting Bulletin No. 104 as described above. For the period from November 15, 2008 (inception) to June 30, 2012, the Company recognized no revenues.

Earnings (Loss) Per Share

The Company computes earnings per share in accordance with ASC 260 “Earnings per Share” which was previously Statement of Accounting Standards No. 128, “Earnings per Share” (“SFAS No. 128”). Under the provisions of SFAS No. 128, basic earnings per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income (loss) for the period by the weighted average number of common and potentially dilutive common shares outstanding during the period. There were no potentially dilutive common shares outstanding during the period.

- 8 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2012

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which was previously Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes.” Under the asset and liability method of Statement 109, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

Fair Value of Financial Instruments

The Company considers that the carrying amount of financial instruments, including accounts payable, approximates fair value because of the short maturity of these instruments.

Share Based Payments

(included in ASC 718 “Compensation-Stock Compensation”)

In December 2004, the FASB issued SFAS No. 123(R), “Share-Based Payment,” which replaces SFAS No. 123 and supersedes APB Opinion No. 25. Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or “SAB 107”. SAB 107 expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS 123.

Effective commencing on the year ended December 31, 2008; the Company has fully adopted the provisions of SFAS No. 123(R) and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

Recent Accounting Pronouncements

The company has adopted all recently issued accounting pronouncements. The adoption of the accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.

NOTE 4 - EQUITY TRANSACTIONS

In November, 2008, the Company issued 9,000,000 shares of common stock to Tammi Shnider, the sole officer and director on that date for $9,000 at $0.001.

In October, 2009, the Company issued 1,000,000 shares of common stock to 39 investors in accordance with Form S-1 (commission file #333-156942) for cash and consideration of $10,000.

In April, 2010, we filed Amended and Restated Articles of Incorporation with the Secretary of State of Florida which:


·	changed the name of the corporation to Rx Technologies Corp.,

·	increased the number of authorized shares of common stock from 100,000,000 shares to 500,000,000 shares and fixed a par value of $0.001 per share,

·	authorized a class of 10,000,000 shares of blank check preferred stock, par value $0.001 per share.

- 98 -

RX TECHNOLOGIES CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

~~JUNE~~SEPTEMBER 30, 2012

In April, 2010, we entered into an Intellectual Property Agreement with the inventor, developer and owner of the RxTC database processes for prescription drug databases and issued 37,221,850 common shares of our company. The issued common shares were allocated, in part, to certain other associates involved with facilitating the development of the intellectual property as defined in the Intellectual Property Agreement.

In December, 2010, the Company issued a total of 8,600,000 common shares to directors (3,000,000 shares), payment of obligation to related party (3,600,000 shares) and payment to consultants (2,000,000 shares).

In February, 2011, we acquired the Intellectual Property Agreement with Medipayments, Inc., the developer and owner of the Medipayments processes for merchant services and issued 5,000,000 common shares as defined in the Intellectual Property Agreement. Additionally, we issued 2,000,000 common shares to consultants of the Medipayments, Inc. transaction.

In March, 2011, the Company issued 1,500,000 shares of common stock to Steven Adelstein, for payment of loans from related parties and authorized the issuance of additional 4,000,000 common shares pursuant to a private placement memorandum.

In June, 2011, the Company issued 1,800,000 shares of common stock to Steven Adelstein, for payment of advances and loans from related parties.

In December, 2011, the Company issued 12,000,000 shares of common stock to related parties and consultants (9,000,000 common shares) and the Board of Directors (3,000,000 common shares) for payment of advances and loans from related parties.

In March, 2012, the Company issued 6,400,000 shares of common stock to related parties for advances, loans and consulting services having a total valuation of $16,000 ($0.0025 per common share).

In June, 2012, the Company issued 9,920,000 shares of common stock to related parties for advances, loans and consulting services having a total valuation of $12,400 ($0.00125 per common share).

The company has no outstanding options and warrants at ~~June~~September 30, 2012.

NOTE 5 - ~~CONCENTRATION~~RELATED OFPARTY ~~CREDIT RISK~~TRANSACTIONS

~~Financial~~From ~~instruments~~time ~~that~~to ~~potentially~~time, ~~subject~~ the ~~Company~~company toborrows ~~concentrations~~from ofits ~~credit~~officers, ~~risk~~directors ~~consist~~and ~~principally~~stockholders. ofAt ~~cash~~September ~~deposits.~~30, ~~Accounts~~2012 atthe ~~each~~company ~~institution~~owed ~~are~~related ~~insured~~parties by$9,000 ~~the~~and ~~Federal~~$5,700 ~~Deposit~~at ~~Insurance~~December ~~Corporation~~31, ~~(“FDIC”)~~2011. AtThere ~~June~~are ~~30,~~no ~~2012,~~signed or executed agreements between the ~~Company~~parties ~~had~~and the company and therefore there are no ~~amounts~~assurances inthat ~~excess~~said ofrelated ~~the~~parties ~~FDIC~~will ~~insured~~advance ~~limit~~funds in the future.

NOTE 6 - RELATED PARTY TRANSACTIONS

From time to time, the company borrows from its officers, directors and stockholders. At June 30, 2012 the company owed related parties in the amount of $0 and $5,700 at December 31, 2011. There are no signed or executed agreements between the parties and the company and therefore there are no assurances that said related parties will advance funds in the future.

The Company does not lease or rent any property. Office space and services are provided without charge by Steven Adelstein, stockholder, our sole officer and director. Such costs are immaterial to the financial statements and, accordingly, have not been reflected therein.

~~The~~NOTE ~~officers~~6 ~~and~~- ~~directors~~INTELLECTUAL of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.PROPERTY

InThe ~~December,~~Company ~~2011~~has ~~and~~capitalized ~~2010,~~costs ~~the~~in ~~officers~~acquiring ~~and~~their ~~directors~~intellectual ~~received~~properties ~~compensation~~which ofconsisted ~~$15,000 (each year) with the issuance~~ of ~~3,000,000 common shares. For~~ the ~~period~~following ~~ended~~at ~~June~~September 30, 2012~~, no compensation to officers and directors, including issuance of common shares, was authorized by the board of directors.~~:

- 10 -


	September 30, 2012

Intellectual Properties	$	68,222
Accumulated Amortization		(6,000	)
Impairment of Valuation		(57,222	)
Total Intellectual Properties, Net	$	5,000

RXThe ~~TECHNOLOGIES~~Company ~~CORP~~amortizes its intellectual properties, using the straight-line method over the estimated useful life of 3 years, once the properties are put into services. At September 30, 2012, both RxTC Solutions and Medipayments have not been put in service and therefore, amortization has not commenced.

(A- ~~DEVELOPMENT~~9 ~~STAGE COMPANY)~~-

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2012

NOTE 7 - INTELLECTUAL PROPERTY

The Company has capitalized costs in acquiring their intellectual properties which consisted of the following at June 30, 2012:

	June 30, 2012
Intellectual Properties	$	68,222
Accumulated Amortization		(6,000	)
Impairment of Valuation		(42,222	)
Total Intellectual Properties, Net	$	20,000

The Company amortizes its intellectual properties, using the straight-line method over the estimated useful life of 3 years, once the properties are put into services. At June 30, 2012, both RxTC Solutions and Medipayments have not been put in service and therefore, amortization has not commenced.

NOTE 8 – SUBSEQUENT EVENTS

We have evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements. Other than the disclosures above, we did not identify any events or transactions that should be recognized or disclosed in the accompanying financial statements.

- 11 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in this Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed on February 23, 2012 with the Securities and Exchange Commission and are hereby referenced.

The statements in this report include forward-looking statements. These forward-looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. You should not rely upon these forward-looking statements as predictions of future events because we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify a forward-looking statement by the use of the forward-terminology, including words such as “may”, “will”, “believes”, “anticipates”, “estimates”, “expects”, “continues”, “should”, “seeks”, “intends”, “plans”, and/or words of similar import, or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. These forward-looking statements relate to, among other things: our sales, results of operations and anticipated cash flows; capital expenditures; depreciation and amortization expenses; sales, general and administrative expenses; our ability to maintain and develop relationship with our existing and potential future customers; and, our ability to maintain a level of investment that is required to remain competitive. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including, but not limited to: variability of our revenues and financial performance; risks associated with technological changes; the acceptance of our products in the marketplace by existing and potential customers; disruption of operations or increases in expenses due to our involvement with litigation or caused by civil or political unrest or other catastrophic events; general economic conditions, government mandates and conditions in the gaming/entertainment industry in particular; and, the continued employment of our key personnel and other risks associated with competition.

For a discussion of the factors that could cause actual results to differ materially from the forward-looking statements see the “Liquidity and Capital Resources” section under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this item of this report and the other risks and uncertainties that are set forth elsewhere in this report or detailed in our other Securities and Exchange Commission reports and filings. We believe it is important to communicate our expectations. However, our management disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

Rx Technologies Corp. (“The Company”) is a development stage company, incorporated in the State of Florida on November 15, 2008. The company, at June 30, 2012 is concentrating on and developing in two (2) primary areas as follows:

1. RxTC Database Processes

The RxTC database (once developed, beta tested and completed) is for prescription drug databases. The RxTC Solution is a secure, easy-to-use and minimum cost service for confronting prescription drug abuse and diversion. The RxTC Solution is a comprehensive secure validation, monitoring and reporting procedure integrated with a visual identification verification system. The process immediately prevents “doctor shopping,” individuals going to more than one physician at a time to obtain prescription drugs. By deploying the RxTC Solution, patient’s identities can be verified and validated. Physicians and pharmacists will immediately have live, real-time data available for scrutiny and could receive important alerts and valid dispensing histories. Secondary verification at the point of dispensing could further eliminate the potential for fraud and other more serious crimes.

2. Medipayments

The Medipayment system (once developed, beta tested and completed) is for payment for prescription drugs and other payments that are required as settlement via a debit card. The Medipayments card will include a back office solution that the consumer can utilize to review payment as made. Additionally, the card shall include data that the merchant can utilize to validate prescription issuance and authorization while maintaining the requirements of both state and federal regulators.

- 10 -

Going Concern

Our financial statements have been prepared on the basis of accounting principles applicable to a going concern. As a result, they do not include adjustments that would be necessary if we were unable to continue as a going concern and would therefore be obligated to realize assets and discharge our liabilities other than in the normal course of operations. As reflected in the accompanying financial statements, the Company is in the development stage with no revenues, has used cash flows in operations of ($3751,~~000~~700) from inception of November 15, 2008 to ~~June~~September 30, 2012 and has an accumulated deficit of ($~~222~~246,~~872~~622) through ~~June~~September 30, 2012.

- 12 -

This raises substantial doubt about our ability to continue as a going concern, as expressed by our auditors in its opinion on our financial statements included in this report. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.

We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on us obtaining adequate capital to fund operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations. There can be no assurance that we will operate at a profit or additional debt or equity financing will be available, or if available, can be obtained on satisfactory terms.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an on-going basis, management evaluates these estimates and assumptions, including but not limited to those related to revenue recognition and the impairment of long-lived assets, goodwill and other intangible assets. Management bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Stock Compensation

(included in ASC 718 “Compensation-Stock Compensation”)

The Company adopted SFAS No. 123R, Share-Based Payment (“SFAS 123R”), which requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company accounts for stock-based compensation arrangements with nonemployees in accordance with the Emerging Issues Task Force Abstract No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services. The Company records the expense of such services to employees and non employees based on the estimated fair value of the equity instrument using the Black-Scholes pricing model.

Revenue Recognition

(included in ASC 605 “Revenue Recognition”)

The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements’ and No. 104, “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured.

Product sales and shipping revenues, net of promotional discounts, rebates, and return allowances, are recorded when the products are shipped and title passes to customers. Retail sales to customers are made pursuant to a sales contract that provides for transfer of both title and risk of loss upon our delivery to the carrier. Return allowances, which reduce product revenue, are estimated using historical experience. Revenue from product sales and services rendered is recorded net of sales taxes. Amounts received in advance for subscription services, are deferred and recognized as revenue over the subscription term.

Outlook

The most important metric by which we judge the Company’s performance now and in the near term is top line sales growth. Our current commitment to develop and deliver quality products means that, for the near future, bottom line profitability will be a poor indicator of our success.

- 11 -

Since investors are certain to be the primary, near term source of liquidity to support our development and marketing efforts, our liquidity will be driven by our ability to attract repeat investments from current shareholders and to find new ones. This in turn may be materially impacted by the general investment climate.

Our primary marketing challenge for the coming 12 months is to achieve market awareness. Additionally, management is seeking new acquisitions to complement existing products.

- 13 -

Revenues

These forward-looking statements, pertaining to revenues, are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. You should not rely upon these forward-looking statements as predictions of future events because we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. As our revenues commence, we plan to invest in marketing and sales by increasing the number of direct sales throughout our web portal to build brand awareness. We expect that in the future, marketing and sales expenses will increase in absolute dollars commencing in the first quarter of 2013. We do not expect our revenues to increase significantly until the latter part of 2013.

General and Administrative Expenses

We expect that general and administrative expenses associated with executive compensation will increase in the future. Although our current president, chief financial officer and sole director have foregone full salary payments during the initial stages of the business, anticipated to commence revenues in the first quarter of 2013. In addition, we believe in the 2013 fiscal year that the compensation packages required to attract the senior executives the Company requires to execute against its business plan will increase our total general and administrative expenses.

Summary of Condensed Results of Operations

Any measurement and comparison of revenues and expenses from continuing operations should not be considered necessarily indicative or interpolated as the trend to forecast our future revenues and results of operations.

Results for the Three Months Ended ~~June~~September 30, 2012 and 2011

Revenues. The Company’s revenues for the three months ended ~~June~~September 30, 2012 and 2011 were $0. From inception (November 15, 2008) through ~~June~~September 30, 2012, the company did not generate any revenues.

Legal and Accounting Expenses. Legal and Accounting expenses for the three months ended ~~June~~September 30, 2012 were $23,~~500~~000 as compared to $42,~~250~~000 for the three months ended ~~June~~September 30, 2011. These expenses are the normal recurring expenses for the quarter including filings with the Securities and Exchange Commission.

General and Administrative Expenses. General and administrative expenses for the three months ended ~~June~~September 30, 2012 were $2,~~400~~750 compared to $21,~~350~~800 for the three months ended ~~June~~September 30, 2011. The increase of $50950 is primarily a result of timing differences for keeping current with the Securities and Exchange Commission filings.

Consulting, Marketing and Advertising Expenses. Consulting, Marketing and Advertising expenses for the three months ended ~~June~~September 30, 2012 were $52,~~000~~500 compared to $0 for the three months ended ~~June~~September 30, 2011. The increase of $52,~~000~~500 is primarily a result of timing differences of development of our actual databases.

Net Loss. Net loss for the three months ended ~~June~~September 30, 2012 was ($923,~~900~~750) as compared to ($63,~~600~~800) for the three months ended ~~June~~September 30, 2011. The loss for the three months ended ~~June~~September 30, 2012 is a reflection of current expenses normalized for the company.

Results for the ~~Six~~Nine Months Ended ~~June~~September 30, 2012 and 2011

Revenues. The Company’s revenues for the ~~six~~nine months ended ~~June~~September 30, 2012 and 2011 were $0. From inception (November 15, 2008) through ~~June~~September 30, 2012, the company did not generate any revenues.

~~Legal~~- ~~and~~12 Accounting Expenses. Legal and Accounting expenses for the six months ended June 30, 2012 were $4,000 as compared to $5,250 for the six months ended June 30, 2011. These expenses are the normal recurring expenses for the quarter including filings with the Securities and Exchange Commission.-

~~General~~Legal and ~~Administrative~~Accounting Expenses. ~~General~~Legal and ~~administrative~~Accounting expenses for the ~~six~~nine months ended ~~June~~September 30, 2012 were $57,~~200~~500 as compared to $37,~~850~~250 for the ~~six~~nine months ended ~~June~~September 30, 2011. ~~The~~These ~~increase~~expenses ofare ~~$1,350~~the isnormal ~~primarily~~recurring aexpenses ~~result~~for ofthe ~~timing~~quarter ~~differences~~including ~~for~~filings ~~keeping current~~ with the Securities and Exchange Commission ~~filings~~.

~~Consulting,~~General ~~Marketing~~ and ~~Advertising~~Administrative Expenses. ~~Consulting,~~General ~~Marketing~~ and ~~Advertising~~administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2012 were $107,~~000~~950 compared to $155,~~000~~650 for the ~~six~~nine months ended ~~June~~September 30, 2011. The ~~decrease~~increase of $52,~~000~~300 is primarily a result of timing differences offor ~~development~~keeping ofcurrent ~~our~~with ~~actual~~the ~~databases~~Securities and Exchange Commission filings.

-Consulting, 14Marketing -and Advertising Expenses. Consulting, Marketing and Advertising expenses for the nine months ended September 30, 2012 were $12,500 compared to $15,000 for the nine months ended September 30, 2011. The decrease of $2,500 is primarily a result of timing differences of development of our actual databases.

Net Loss. Net loss for the ~~six~~nine months ended ~~June~~September 30, 2012 was ($1942,~~200~~950) as compared to ($2529,~~934~~734) for the ~~six~~nine months ended ~~June~~September 30, 2011. The loss for the ~~six~~nine months ended ~~June~~September 30, 2012 is a reflection of current expenses normalized for the company.

Impact of Inflation

We believe that the rate of inflation has had negligible effect on our operations. We believe we can absorb most, if not all, increased non-controlled operating costs by increasing sales prices, whenever deemed necessary and by operating our Company in the most efficient manner possible.

Liquidity and Capital Resources

The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. Since its inception, the Company has been funded by its related parties and equity sales.

As of ~~June~~September 30, 2012, total current assets were $0

As of ~~June~~September 30, 2012, total current liabilities were $312,~~750~~500 which consisted of $3,~~750~~500 of accrued expenses and $9,000 of loans from related parties. As of December 31, 2011, total current liabilities were $12,950, which consisted of $7,250 of accrued expenses and $5,700 of loans to related parties. We had net working capital deficit of ($312,~~750~~500) as of ~~June~~September 30, 2012 and ($12,950) at December 31, 2011.

During the ~~six~~nine months ended ~~June~~September 30, 2012, operating activities ~~provided~~used cash of $59,~~700~~000.

Material Commitments

The Company does not have any material commitments as of ~~June~~September 30, 2012.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or any anticipate entering into any off-balance arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Recent Accounting Pronouncements

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are not subject to risks related to foreign currency exchange rate fluctuations. Our functional currency is the United States dollar. We do not transact our business in other currencies. As a result, we are not subject to exposure from movements in foreign currency exchange rates. We do not use derivative financial instruments for speculative trading purposes.

- 13 -

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that the information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Treasurer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

InAs ~~designing~~required ~~and~~by ~~evaluating~~SEC ~~the~~Rule ~~disclosure~~13a-15(b), ~~controls~~we ~~and~~carried ~~procedures,~~out ~~management~~an ~~recognized~~evaluation, ~~that~~under ~~any~~the ~~controls~~supervision and ~~procedures,~~with nothe ~~matter~~participation ~~how~~of ~~well~~our ~~designed~~management, ~~and~~including ~~operated~~our President, ~~can~~of ~~only~~the ~~provide~~effectiveness ~~reasonable~~of ~~assurance~~the ofdesign ~~achieving~~and ~~the~~operation ~~desired~~of ~~control~~our ~~objectives,~~disclosure controls and inprocedures ~~reaching~~as aof ~~reasonable~~the ~~level~~end of ~~assurance,~~our ~~management~~third ~~necessarily~~fiscal ~~was~~quarter ~~required~~covered toby ~~apply~~this ~~its~~report. ~~judgment~~Based inon ~~evaluating~~ the ~~cost-benefit~~foregoing, ~~relationship~~our ofPresident ~~possible~~concluded that our disclosure controls and procedures were not effective at the reasonable assurance level.

AsThere ~~required~~has bybeen ~~SEC~~no ~~Rule~~change ~~13a-15(b),~~in ~~we carried out an evaluation, under the supervision and with the participation of~~ our ~~management,~~internal ~~including our President and Treasurer, of the effectiveness of the design and operation of our disclosure~~ controls ~~and~~over ~~procedures~~financial asreporting ofduring ~~the end of~~ our ~~first~~third fiscal quarter ~~covered~~ended bySeptember ~~this~~30, ~~report.~~2012, ~~Based~~that onhas ~~the~~materially ~~foregoing~~affected, ~~our~~or ~~President~~is ~~and~~reasonably ~~Treasurer~~likely ~~concluded~~to ~~that~~materially affect, our ~~disclosure~~internal controls ~~and~~over ~~procedures~~financial ~~were effective at the reasonable assurance level~~reporting.

-MANAGEMENT’S 15REMEDIATION -INITIATIVES

~~There~~In ~~has~~an ~~been~~effort noto ~~change~~remediate inthe ~~our~~identified ~~internal~~material ~~controls~~weaknesses ~~over~~and ~~financial~~other ~~reporting~~deficiencies ~~during~~and enhance our ~~first~~internal ~~fiscal~~controls, ~~quarter~~we ~~that~~have ~~has materially affected~~initiated, or isplan ~~reasonably likely~~ to ~~materially affect~~initiate, ~~our~~the ~~internal~~following ~~controls~~series ~~over~~of ~~financial reporting.~~measures:

We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. And, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.

Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board.

We anticipate that these initiatives will be at least partially, if not fully, implemented by September 30, 2012. Additionally, we plan to test our updated controls and remediate our deficiencies by March 31, 2013.

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING

There has been no change in our internal controls over financial reporting during our third fiscal quarter ended September 30, 2012, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceeding.

None.

Item 1A. Risk Factors.

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~In June, 2012, the Company issued a total of 9,920,000 common shares to related parties (Steven Adelstein)~~None. ~~These shares were issued as payment of debt at $0.00125 per common share for a total of $12,400.~~

Management believes the above shares of common stock were issued pursuant to the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended.

Item 3. Defaults Upon Senior Securities.

None.

- 14 -

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

(a) Exhibits


Exhibit No.	Description

31.1	Rule 13a-14(a)/15d-14(a) Certification of President and Principal Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer and Principal Accounting Officer
32.1	Section 1350 Certification of President and Principal Executive Officer
32.2	Section 1350 Certification of Chief Financial Officer and Principal Accounting Officer
101*	XBRL data files of Financial Statements and Notes contained in this Quarterly Report on Form 10-Q

* InTo ~~accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall~~ be ~~deemed~~submitted ~~“furnished”~~by ~~and not “filed~~amendment.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		RX TECHNOLOGIES CORP.
DATE: August 2, 2012	By:	/s/ Michael McManus
DATE: December 11, 2012	By:	/s/ Michael McManus
		Michael McManus
		President and Principal Executive Officer

- 1615 -

Filing Compare · Rx Technologies Corp.